Human plasma distribution of free paclitaxel and paclitaxel associated with diblock copolymers

被引:84
作者
Ramaswamy, M
Zhang, XC
Burt, HM
Wasan, KM
机构
[1] UNIV BRITISH COLUMBIA,FAC PHARMACEUT SCI,DIV PHARMACEUT & BIOPHARMACEUT,VANCOUVER,BC V6T 1Z3,CANADA
[2] ANGIOTECH PHARMACEUT INC,VANCOUVER,BC,CANADA
关键词
METASTATIC BREAST-CANCER; LIPID TRANSFER PROTEIN; PHASE-II TRIAL; CREMOPHOR-EL; SERUM-LIPOPROTEINS; AMPHOTERICIN-B; LUNG-CANCER; TAXOL; BINDING; DRUG;
D O I
10.1021/js960333n
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Amphiphilic diblock copolymer poly (D,L-lactide)-block-methoxy polyethylene glycol was synthesized, and paclitaxel (Taxol) was incorporated into this copolymer above its critical micelle concentration (cmc), resulting in the formation of polymeric micellar paclitaxel (PMT). Free paclitaxel dissolved in acetonitrile (TAX) and PMT, at 10 mu g of paclitaxel/mL of human plasma, were incubated for 5, 30, and 60 min at 37 degrees C. Following incubation, the plasma was separated into its high-density (HDL), low-density (LDL), very-low-density (VLDL) lipoprotein and lipoprotein-deficient (LPDP) plasma fractions by density gradient ultracentrifugation. Each of these lipoprotein (LP) and LPDP fractions were analyzed for paclitaxel and plasma lipid levels by well-established HPLC and enzymatic assays. When TAX was incubated in human plasma for 5 min, an equal amount of drug was found in the LP and LPDP fractions. This distribution profile did not change following incubation for 30 and 60 min. Of the amount of TAX that was distributed within the LP fraction, 70-75% of TAX was associated with the HDL fraction for all time points studied. The paclitaxel plasma and LP distribution profile for PMT was similar to the distribution profile of TAX, suggesting that the plasma and LP distribution of paclitaxel is independent of the method of paclitaxel delivery and that LP distribution is not a function of mass lipid levels.
引用
收藏
页码:460 / 464
页数:5
相关论文
共 39 条
[1]  
ALEXOPOULOS CG, 1987, CANCER-AM CANCER SOC, V60, P3065, DOI 10.1002/1097-0142(19871215)60:12<3065::AID-CNCR2820601234>3.0.CO
[2]  
2-Q
[3]   A MIXED MICELLAR FORMULATION SUITABLE FOR THE PARENTERAL ADMINISTRATION OF TAXOL [J].
ALKANONYUKSEL, H ;
RAMAKRISHNAN, S ;
CHAI, HB ;
PEZZUTO, JM .
PHARMACEUTICAL RESEARCH, 1994, 11 (02) :206-212
[4]   UNUSUAL SERUM LIPOPROTEIN ABNORMALITY INDUCED BY VEHICLE OF MICONAZOLE [J].
BAGNARELLO, AG ;
LEWIS, LA ;
MCHENRY, MC ;
WEINSTEIN, AJ ;
NAITO, HK ;
MCCULLOUGH, AJ ;
LEDERMAN, RJ ;
GAVAN, TL .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 296 (09) :497-499
[5]   CONTROLLED DELIVERY OF TAXOL FROM MICROSPHERES COMPOSED OF A BLEND OF ETHYLENE-VINYL ACETATE COPOLYMER AND POLY (D,L-LACTIC ACID) [J].
BURT, HM ;
JACKSON, JK ;
BAINS, SK ;
LIGGINS, RT ;
OKTABA, AMC ;
ARSENAULT, AL ;
HUNTER, WL .
CANCER LETTERS, 1995, 88 (01) :73-79
[6]  
CHERVINSKY DS, 1993, ANTICANCER RES, V13, P93
[7]   Solubility and stability of taxol: Effects of buffers and cyclodextrins [J].
Dordunoo, SK ;
Burt, HM .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1996, 133 (1-2) :191-201
[8]  
Dorr R T, 1994, Ann Pharmacother, V28, pS11
[9]  
Goldspiel B R, 1994, Ann Pharmacother, V28, pS23
[10]  
GREENWALD RB, 1993, J CONTROL RELEASE, V24, P119